Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, in animal models, dopamine D1 receptor knockout rats will not self-administer cocaine37 and μ opioid receptor knockout mice will not show the rewarding effects of opioids.153”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [153]
In the citing paper
“Mice that lack the MOR gene do not develop place preferences or withdrawal symptoms in response to morphine (Matthes et al 1996).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Matthes et al 1996
Citations
Cites
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Self-citationNeutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
Roques, B. P., Noble, F., Daugé, V, Fournié-Zaluski, M. C., & Beaumont, A. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00449-1 · Cited by 756
Self-citationLufkin, T., Dierich, A., LeMeur, M., Mark, M., & Chambon, P. (1991) · Cell · doi:10.1016/0092-8674(91)90034-v · Cited by 697
Self-citationChiara, G. D., & Alan North, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90062-b · Cited by 543
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., & Nestler, E. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91111-d · Cited by 535
A brief history of opiates, opioid peptides, and opioid receptors.
Brownstein, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5391 · Cited by 491
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
Kieffer, B. L. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071128 · Cited by 389
Self-citationReduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., & Schütz, G. (1996) · Science · doi:10.1126/science.273.5275.657 · Cited by 292
Self-citationThe mouse Pgk-1 gene promoter contains an upstream activator sequence
McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193
Research works printed but not linked: 9
- Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
- Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
- Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
- Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
- Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
- Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
- Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
- Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
- Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Cited by
Items 401–500 of 1,002
Quantitative autoradiography of μ-,δ- and κ1 opioid receptors in κ-opioid receptor knockout mice
Slowe, S. J., Simonin, F., Kieffer, B. L., & Kitchen, I. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01201-3 · Cited by 90
Self-citationAn Emerging Role for the Delta Opioid Receptor in the Regulation of Mu Opioid Receptor Function
Rozenfeld, R., Abul‐Husn, N. S., Gomez, I., & Devi, L. A. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.219 · Cited by 71
“While it is clear that morphine-induced analgesia is mediated by MOR activation (since this phenomenon is lost by MOR gene deletion[8]), the role of DOR in analgesia remains unclear since, in some”
BackgroundFunctional characterization of human variants of the mu-opioid receptor gene
Ravindranathan, A., Joslyn, G., Robertson, M. A., Schuckit, M. A., Whistler, J. L., & White, R. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904509106 · Cited by 72
“Previous experiments have demonstrated a 60% decrease in MOR binding (38), as well as reduced sensitivity to morphine in heterozygous MOR deficient mice (39, 40).”
Selective Interference of β-Arrestin 1 with κ and δ but Not μ Opioid Receptor/G Protein Coupling
Cheng, Z.-J. J., Yu, Q., Wu, Y., Ma, L., & Pei, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24328 · Cited by 71
Cunningham, C. L., Dickinson, S. D., Grahame, N. J., Okorn, D. M., & McMullin, C. S. (1999) · Psychopharmacology · doi:10.1007/s002130051090 · Cited by 80
Transcriptional Regulation of Mouse δ-Opioid Receptor Gene
Liu, H.-C., Shen, J.-T., Augustin, L. B., KO, J. L., & Loh, H. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23617 · Cited by 70
Imaging pain modulation in health and disease
Bingel, U., Schoell, E., & B??chel, C. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328259c34d · Cited by 70
Opioid switching and rotation in primary care: implementation and clinical utility
Slatkin, N. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903120158 · Cited by 73
Synapse-specific opioid modulation of thalamo-cortico-striatal circuits
Birdsong, W. T., Jongbloets, B. C., Engeln, K. A., Wang, D., Scherrer, G., & Mao, T. (2019) · eLife · doi:10.7554/elife.45146 · Cited by 72
Optimizing Functional versus Total Expression of the Human μ-Opioid Receptor in Pichia pastoris
Sarramégna, V., Demange, P., Milon, A., & Talmont, F. (2002) · Protein Expression and Purification · doi:10.1006/prep.2001.1564 · Cited by 70
Alternative Splicing Determines the Post-endocytic Sorting Fate of G-protein-coupled Receptors
Tanowitz, M., Hislop, J. N., & von Zastrow, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806588200 · Cited by 70
Ligand-Induced Changes in Surface μ-Opioid Receptor Number: Relationship to G Protein Activation?
Zaki, P. A., Keith, D. E., Brine, G. A., Carroll, F. I., & Evans, C. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35398-4 · Cited by 70
Selley, D. E., Cao, C., Liu, Q., & Childers, S. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703382 · Cited by 70
“…the only report to examine the e ects of sodium on agonist e cacy for stimulation of [35S]-GTPgS binding with the m-opioid receptor, which is primarily responsible for mediating the analgesic, reinforcing and dependence e ects of clinically relevant opiates such as morphine (Matthes et al., 1996).”
BackgroundEmergence of Functional δ-Opioid Receptors Induced by Long-Term Treatment with Morphine
Ma, J., Zhang, Y., Kalyuzhny, A., & Pan, Z. Z. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019109 · Cited by 72
“…using opioid receptor knockout mice, have clearly established that the -opioid receptor is predominantly responsible for mediating major opioid actions, including analgesia, reward, and the development of opioid tolerance and dependence (Matthes et al., 1996; Sora et al., 1997; Kieffer, 2000).”
BackgroundIde, S., Minami, M., Satoh, M., Uhl, G. R., Sora, I., & Ikeda, K. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300463 · Cited by 75
“These results provide a sharp contrast to the virtually complete loss of rewarding effects of morphine in place preference assays using either these or other strains of homozygous MOR-KO mice (Matthes et al, 1996; Sora et al, 2001).”
BackgroundResultCurrent strategies toward safer mu opioid receptor drugs for pain management
Ehrlich, A. T., Kieffer, B. L., & Darcq, E. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1586882 · Cited by 74
“target of most opioid drug discovery programs [7,8].”
BackgroundSelf-citationOpioid genetics: the key to personalized pain control?
Branford, R., Droney, J., & Ross, J. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01923.x · Cited by 68
“Knockout studies in mice show that the μ-opioid receptor is essential for morphine-induced analgesia (5).”
BackgroundPharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates
Haile, C. N., Kosten, T. A., & Kosten, T. R. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802122564 · Cited by 80
“More specifically, “knock-out” mouse strains lacking the opioid mu-receptor gene (OPRM1) demonstrate impaired response not only to the rewarding and physiological effects of opiate compounds (104) but also to alcohol (42).”
BackgroundCharbogne, P., Gardon, O., Martín-García, E., Keyworth, H. L., Matsui, A., Mechling, A. E., Bienert, T., Nasseef, T., Robé, A., Moquin, L., et al. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.022 · Cited by 69
Self-citationLefevre, E. M., Pisansky, M. T., Toddes, C., Baruffaldi, F., Pravetoni, M., Tian, L., Kono, T. J. Y., & Rothwell, P. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0643-x · Cited by 66
Van den Berg, C. L., Van Ree, J. M., Spruijt, B. M., & Kitchen, I. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00717.x · Cited by 69
Self-citationRoulet, L., Rollason, V., Desmeules, J. A., & Piguet, V. (2021) · Drugs · doi:10.1007/s40265-021-01515-z · Cited by 87
“From a pharmacological point of view, it is not possible to completely dissociate the analgesic activity and adverse effects of opioids to the extent that they are mediated by the same type of receptor [5].”
BackgroundContet, C., Filliol, D., Matifas, A., & Kieffer, B. L. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.10.015 · Cited by 70
Self-citationPlacebo-induced analgesia in an operant pain model in rats
Nolan, T. A., Price, D. D., Caudle, R. M., Murphy, N. P., & Neubert, J. K. (2012) · Pain · doi:10.1016/j.pain.2012.04.026 · Cited by 76
“Genetic deletion of some (but not all) endogenous opioids attenuates the expectancy of rewards [15,23,37,41].”
BackgroundDrugs of Abuse and Brain Gene Expression
Torres, G., & Horowitz, J. M. (1999) · Psychosomatic Medicine · doi:10.1097/00006842-199909000-00007 · Cited by 75
“not exhibit morphine-induced analgesia, reward, or withdrawal symptoms after a naloxone challenge (211).”
BackgroundCrawley, J. N. (2000) · ILAR Journal · doi:10.1093/ilar.41.3.136 · Cited by 68
“Self-administration of drugs of abuse, including alcohol, cocaine, morphine, and nicotine, are measured in mice (Belknap et al. 1993; Berrettini et al. 1994; Grahame and Cunningham 1995; Alexander et al. 1996; Matthes et al. 1996; Grisel et al. 1997; Miner 1997; Maldonado et al. 1997; Picciotto et al. 1998; Crabbe et…”
BackgroundOzaita, A., Escribá, P. V., Ventayol, P., Murga, C., Mayor, F., & García-Sevilla, J. A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70031249.x · Cited by 67
Fuchs, P. N., Roza, C., Sora, I., Uhl, G., & Raja, S. N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01060-4 · Cited by 67
SPIKE, R. C., Puskár, Z., Sakamoto, H., Stewart, W. B., Jr., Watt, C., & Todd, A. J. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01969.x · Cited by 67
“Mice in which the MOR-1 gene has been deleted fail to show morphine analgesia (Matthes et al., 1996), indicating that products of this gene are responsible for the analgesia.”
BackgroundDistinct µ-opioid ensembles trigger positive and negative fentanyl reinforcement
Chaudun, F., Python, L., Liu, Y., Hiver, A., Cand, J., Kieffer, B. L., Valjent, E., & Lüscher, C. (2024) · Nature · doi:10.1038/s41586-024-07440-x · Cited by 76
“Additionally, brain-wide genetic deletion of the µ-opioid receptors (µORs) prevents the induction of positive and negative reinforcement, as both conditioned place preference (CPP) and withdrawal are abolished in these mice 5 .”
BackgroundSelf-citationYu, Y. J., Arttamangkul, S., Evans, C. J., Williams, J. T., & von Zastrow, M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4315-08.2009 · Cited by 66
“The -opioid receptor (MOR) is the primary target mediating analgesic, euphoric, and reinforcing effects of morphine (Matthes et al., 1996).”
Endogenous Orphanin FQ/Nociceptin Is Involved in the Development of Morphine Tolerance
Chung, S., Pohl, S., Zeng, J., Civelli, O., & Reinscheid, R. K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103960 · Cited by 66
Schoenfuss, H. L., Furlong, E. T., Phillips, P. J., Scott, T., Kolpin, D. W., Ćetković-Cvrlje, M., Lesteberg, K. E., & Rearick, D. C. (2015) · Environmental Toxicology and Chemistry · doi:10.1002/etc.3147 · Cited by 71
Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine
Xu, J., Lu, Z., Narayan, A., Le Rouzic, V. P., Xu, M., Hunkele, A., Brown, T. G., Hoefer, W. F., Rossi, G. C., Rice, R. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88760 · Cited by 66
Extensive overlap of mu-opioid and nicotinic sensitivity in cortical interneurons
Ferezou, I., Hill, E. L., Cauli, B., Gibelin, N., Kaneko, T., Rossier, J., & Lambolez, B. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhl104 · Cited by 65
“…interneurons coexpress the a4, a5, and b2 nicotinic receptor subunits (Porter et al. 1999; Christophe et al. 2002) and MOR and thus constitute the primary target of both nicotine and opiates (Matthes et al. 1996; Marubio and Changeux 2000; Picciotto et al. 2000; Salas et al. 2003) in the neocortex.”
BackgroundWhy mu‐opioid agonists have less analgesic efficacy in neuropathic pain?
Martínez‐Navarro, M., Maldonado, R. J., & Baños, J.-E. (2018) · European Journal of Pain · doi:10.1002/ejp.1328 · Cited by 72
“Currently, available opioids produce their pharmacological effects mainly by activation of MOR (Matthes et al., 1996) and opioids used for pain are usually described as “mu agonists.””
BackgroundSelf-citationThe role of the M1/M2 microglia in the process from cancer pain to morphine tolerance
Tu, H., Chu, H., Guan, S., Hao, F., Xu, N., Zhao, Z., & Liang, Y. (2020) · Tissue and Cell · doi:10.1016/j.tice.2020.101438 · Cited by 74
He, L., Gooding, S. W., Lewis, E., Felth, L. C., Gaur, A., & Whistler, J. L. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01054-x · Cited by 66
How to design an opioid drug that causes reduced tolerance and dependence
Berger, A. C., & Whistler, J. L. (2010) · Annals of Neurology · doi:10.1002/ana.22002 · Cited by 65
“The biological actions, both desired and undesired, of morphine and other narcotic analgesics are mediated primarily by the mu opioid receptor (MOR), as they are abolished by MOR-specific antagonists and in MOR knockout (KO) mice.(2) In our laboratory, we study the effect of MOR trafficking and hetero-oligomerization…”
BackgroundJavelot, H., Messaoudi, M., Garnier, S., & Rougeot, C. (2010) · PubMed · Cited by 65
Chen, H., Noble, F., Coric, P., Fournié‐Zaluski, M., & Roques, B. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12028 · Cited by 65
Self-citationUncovering patterns of atomic interactions in static and dynamic structures of proteinsPreprint
Venkatakrishnan, A., Fonseca, R., Ma, A. K., Hollingsworth, S. A., Chemparathy, A., Hilger, D., Kooistra, A. J., Ahmari, R., Babu, M. M., Kobilka, B. K., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/840694 · Cited by 72
“They are also important drug targets for the treatment of pain (Matthes et al. 1996) (Vanderah 2010) and have potential for development as targets for the treatment of brain disorders (PMID: 21925742).”
BackgroundMediation of opioid analgesia by a truncated 6-transmembrane GPCR
Lu, Z., Xu, J., Rossi, G. C., Majumdar, S., Pasternak, G. W., & Pan, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81070 · Cited by 66
Crist, R. C., Ambrose‐Lanci, L. M., Vaswani, M., Clarke, T., Zeng, A. M., Yuan, C., Ferraro, T. N., Hakonarson, H. H., Kampman, K. M., Dackis, C. A., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.06.023 · Cited by 66
A Continuous, Fluorescence-based Assay of µ-Opioid Receptor Activation in AtT-20 Cells
Knapman, A., Santiago, M., Du, Y. P., Bennallack, P. R., Christie, M. J., & Connor, M. A. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112461376 · Cited by 63
“The μ–opioid receptor (MOR) is the primary site of action for most clinically important opioid drugs and, as such, is the major target for the development of improved opioid analgesic drugs.(2) It is generally accepted that there are no functionally important subtypes of MOR,(3) and so aside from novel formulations or…”
BackgroundWalwyn, W. M., Chen, W., Kim, H., Minasyan, A., Ennes, H. S., McRoberts, J. A., & Marvizón, J. C. G. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1751-15.2016 · Cited by 63
“Male or female mice lacking MORs (MOR KO) (Matthes et al., 1996), pre-pro-enkephalin (pENK KO) (König et al., 1996), pro-opiomelanocortin (pOMC KO) (Rubinstein et al., 1996), and pre-pro-dynorphin (pDYN KO) (Sharifi et al., 2001) and their WT littermates and were bred from heterozygotes matings of…”
BackgroundResultInfluentialZhang, Y., Chen, S.-R., Laumet, G. O., Chen, H., & Pan, H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.711812 · Cited by 70
The NK1 Receptor Is Essential for the Full Expression of Noxious Inhibitory Controls in the Mouse
Bester, H., Felipe, C. D., & Hunt, S. P. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-03-01039.2001 · Cited by 64
“…ventromedial nucleus of the hypothalamus (VMH), periaqueductal gray (PAG), and RVM in mediating antinociception generated by opiates, local brain stimulation, and stress-induced analgesia (Kelly and Franklin, 1984; Jones and Light, 1990; Matthes et al., 1996; Fields, 2000; Valverde et al., 2000).”
BackgroundMu‐opioid receptors are involved in the tolerance to nicotine antinociception
Galeote, L., Kieffer, B. L., Maldonado, R., & Berrendero, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03751.x · Cited by 64
Self-citationBroadbear, J. H., Sumpter, T. L., Burke, T. F., Husbands, S. M., Lewis, J. W., Woods, J. H., & Traynor, J. R. (2000) · PubMed · Cited by 64
Reiss, D. J., Maduna, T., Maurin, H., Audouard, E., & Gavériaux‐Ruff, C. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24626 · Cited by 68
Zhang, D., Shao, C., Shao, M., Yan, P., Wang, Y., Liu, Y., Liu, W., Lin, T., Xie, Y., Zhao, Y., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.012 · Cited by 70
Nelson, A. M., Battersby, A. S., Baghdoyan, H. A., & Lydic, R. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181bdf894 · Cited by 66
Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal
Harris, A. C., & Gewirtz, J. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2155-0 · Cited by 63
“Opioid receptor subtypes Studies using both pharmacological (DeLander et al. 1984; Maldonado et al. 1992) and genetic (Matthes et al. 1996) manipulations have strongly implicated the mu receptor subtype in chronic opioid dependence.”
BackgroundCui, Y., Zhang, X. Q., Cui, Y., Xin, W., Jin, J., & Liu, X. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.064 · Cited by 73
Crosstalk between chemokines and neuronal receptors bridges immune and nervous systems
Zhang, N., & Oppenheim, J. J. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0405224 · Cited by 69
“DNA sequence analysis reveals that opioid receptors belong to a superfamily of seven transmembrane receptors and consist of three subtypes: -, -, and -opioid receptors [16, 17].”
BackgroundA Novel Alternatively Spliced Isoform of the Mu-Opioid Receptor: Functional Antagonism
Gris, P., Gauthier, J., Cheng, P., Gibson, D. G., Gris, D., Laur, O., Pierson, J., Wentworth, S., Nackley, A. G., Maixner, W. D., et al. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-33 · Cited by 73
“Background The μ-opioid receptor (MOR) is the primary target for both endogenous and exogenous opioid analgesics, mediating basal nociception as well as agonist responses [1-4].”
BackgroundRougeot, C., Robert, F., Menz, L., Bisson, J. F., & Messaoudi, M. (2010) · PubMed · Cited by 62
RGS9‐2 is a negative modulator of μ‐opioid receptor function
Psifogeorgou, K., Papakosta, P., Russo, S. J., Neve, R. L., Kardassis, D., Gold, S. J., & Zachariou, V. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04812.x · Cited by 63
Morphine Induces Desensitization of Insulin Receptor Signaling
Li, Y., Eitan, S., Wu, J., Evans, C. J., Kieffer, B., Sun, X., & Polakiewicz, R. D. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6255-6266.2003 · Cited by 63
“Male MOR knockout (40) and littermate control mice 10”
BackgroundSelf-citationOlmedo, R., & Hoffman, R. S. (2000) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(05)70124-3 · Cited by 68
LaForge, K. S., Shick, V. V., Spangler, R., Proudnikov, D., Yuferov, V. P., Lysov, Y., Mirzabekov, A. D., & Kreek, M. J. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001009)96:5<604::aid-ajmg5>3.0.co;2-f · Cited by 68
“Studies in mice with targeted deletions of the mu opioid receptor gene indicate that both the analgesic and rewarding properties of morphine are primarily mediated by this receptor [Matthes et al., 1996; Sora et al., 1997; Tian et al., 1997; Loh et al., 1998].”
BackgroundPharmacogenetics of Alcohol and Alcohol Dependence Treatment
Kranzler, H. R., & Edenberg, H. J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791516387 · Cited by 66
“Mice lacking the μopioid receptor [11, 12] show a loss of morphine-induced analgesia, reward, and withdrawal symptoms.”
BackgroundGreeneltch, K. M., Haudenschild, C. C., Keegan, A. D., & Shi, Y. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2003.12.001 · Cited by 68
Opioid receptors: toward separation of analgesic from undesirable effects
Law, P., Reggio, P. H., & Loh, H. H. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.03.003 · Cited by 68
Maldonado, R. J., & Valverde, O. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.001 · Cited by 67
Self-citationAssociation between human μ‐opioid receptor gene polymorphism, pain tolerance, and opioid addiction
Compton, P. A., Geschwind, D. H., & Alarcón, M. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20057 · Cited by 67
“The murine m-opioid receptor (Oprm) gene has been identified as the strong candidate locus for the pleiotropic expression of this genotype [Berrettini et al., 1994; Belknap et al., 1995; Mogil et al., 1995, 1996; Matthes et al., 1996; Mogil and Grisel, 1998; Mogil, 1999; Uhl et al., 1999].”
BackgroundLyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence
Wilson, L., Harris, H. M., Eans, S. O., Brice‐Tutt, A. C., Cirino, T. J., Stacy, H. M., Simons, C. A., León, F., Sharma, A., Boyer, E. W., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108310 · Cited by 66
“Rewarding effects are attributed to the agonist-induced suppression of inhibitory interneurons, thereby indirectly increasing the activity of dopaminergic A10 neurons in the brain reward pathway (Matthes et al., 1996).”
Degradable polymeric vehicles for postoperative pain management
Brigham, N. C., Ji, R., & Becker, M. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21438-3 · Cited by 65
Ananthan, S., Saini, S. K., Dersch, C. M., Xu, H., McGlinchey, N., Giuvelis, D., Bilsky, E. J., & Rothman, R. B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300686p · Cited by 64
Zhang, Y., Picetti, R., Butelman, E. R., Ho, A., Blendy, J. A., & Kreek, M. J. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.286 · Cited by 64
“Neuropsychopharmacology low doses of cocaine (Matthes et al, 1996; Sora et al, 1997; Becker et al, 2000; Sora et al, 2001).”
Pharmacogenomics of the Human µ-Opioid Receptor
Kasai, S., & Ikeda, K. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.68 · Cited by 67
Koob, G. F., Roberts, A. J., Kieffer, B. L., Heyser, C. J., Katner, S. N., Ciccocioppo, R., & Weiss, F. (2002) · Springer eBooks · doi:10.1007/0-306-47939-7_19 · Cited by 66
“In one study, µ-opioid receptor knockout mice were prepared using methods described previously ( Matthes, Maldonado, Simonin, Valverde, Slowe, Kitchen, Befort, Dierich, Le Meur, Dolle, Tzavara, Hanoune, Roques, & Kieffer, 1996 ).”
Self-citationA role of RGS proteins in drug addiction
Hooks, S. B., Martemyanov, K. A., & Zachariou, V. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.045 · Cited by 70
Sora, I., Li, X.-F., Funada, M., Kinsey, S., & Uhl, G. R. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00933-9 · Cited by 61
Sánchez‐Blázquez, P., Rodríguez‐Díaz, M., DeAntonio, I., & Garzón, J. (1999) · PubMed · Cited by 61
Morinville, A., Cahill, C. M., Kieffer, B. L., Collier, B., & Beaudet, A. (2004) · Pain · doi:10.1016/j.pain.2004.01.011 · Cited by 61
“The generation of mOR KO mice has been described in detail previously (Matthes et al., 1996).”
Self-citationMansikka, H. T., Zhao, C., Sheth, R. N., Sora, I., Uhl, G. R., & Raja, S. N. (2004) · Anesthesiology · doi:10.1097/00000542-200404000-00022 · Cited by 65
Jin, J., Kittanakom, S., Wong, V., Reyes, B. A. S., Bockstaele, E. J. V., Štagljar, I., Berrettini, W. H., & Levenson, R. G. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-33 · Cited by 62
“MOR knockout mice display significantly reduced sensitivity to both the analgesic and rewarding effects of opioids, thus confirming the importance of the MOR in analgesia and opioid dependence [9,10].”
BackgroundVathy, I., Šlamberová, R., Rimanóczy, Á., Riley, M. A., & Bar, N. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00355-x · Cited by 62
Rewarding Morphine-Induced Synaptic Function of δ-Opioid Receptors on Central Glutamate Synapses
Bie, B., Zhu, W. J., & Pan, Z. Z. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.148908 · Cited by 59
“…clearly that MOR plays an essential role in all major actions of opioids, including opioid reward and addiction, as genetic deletion or pharmacological blockade of MOR abolishes opioid-induced rewarding effect and associated behaviors of opioid addiction (Matthes et al., 1996; Contet et al., 2004).”
BackgroundHosohata, Y., Vanderah, T. W., Burkey, T. H., Ossipov, M. H., Kovelowski, C. J., Sora, I., Uhl, G. R., Zhang, X., Rice, K. C., Roeske, W. R., et al. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00897-3 · Cited by 60
Dockstader, C. L., & van der Kooy, D. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-22-09077.2001 · Cited by 63
“…cue (Skinner and Martin, 1992; Jaeger and van der Kooy, 1996), has anxiolytic effects (Costall et al., 1989), has powerful motivational effects (Matthes et al., 1996; David and Cazala, 2000; Narita et al., 2000; Dockstader et al., 2001), and alters locomotion in drug activation (Browne and…”
BackgroundDel Boca, C., Lutz, P. E., Le Merrer, J., Koebel, P., & Kieffer, B. L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.022 · Cited by 59
“Each mouse was immediately placed into a Plexiglas transparent box (15×15×30 cm) and observed individually during 20 min for signs of withdrawal (Matthes et al, 1996, Frenois et al., 2002).”
Self-citationLópez‐Giménez, J. F., Vilaró, M. T., & Milligan, G. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.048272 · Cited by 59
“It is likely, therefore, that cross-regulation of signals may occur and that concurrent exposure to agonist ligands for two distinct GPCRs may alter signal output and receptor regulation (Hur and Kim, 2002).”
BackgroundInfluentialBiological activity of plant extracts: novel analgesic drugs
Calixto, J. Β., Scheidt, C., Otuki, M. F., & Santos, A. R. S. (2001) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.6.2.261 · Cited by 87
Presynaptic Mechanism for Anti-Analgesic and Anti-Hyperalgesic Actions of κ-Opioid Receptors
Bie, B., & Pan, Z. Z. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-19-07262.2003 · Cited by 59
Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor ε1 subunit
Miyamoto, Y., Yamada, K., Nagai, T., Mori, H., Mishina, M., Furukawa, H., Noda, Y., & Nabeshima, T. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03086.x · Cited by 60
Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice
Rice, O. V., Gordon, N., & Gifford, A. N. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02890-1 · Cited by 58
Cinque, C., Pondiki, S., Oddi, D., Certo, M. G. D., Marinelli, S., Troisi, A., Moles, A., & D'Amato, F. R. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.83 · Cited by 63
“The generation of mice lacking m-opioid receptors was previously described.(21) WT and m-KO subjects of these experiments derived from homozygous breeding pairs.”
BackgroundMcQuiston, A. R., & Saggau, P. (2003) · Journal of Neurophysiology · doi:10.1152/jn.01150.2002 · Cited by 67
Kapur, S., Sharad, S., SINGH, R. A., & Gupta, A. K. (2007) · Journal of Integrative Neuroscience · doi:10.1142/s0219635207001635 · Cited by 62
A role for the mu opioid receptor in the antidepressant effects of buprenorphine
Robinson, S. A., Erickson, R. L., Browne, C. A., & Lucki, I. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.050 · Cited by 58
Lack of opioid or dopaminergic effects on unconditioned sexual incentive motivation in male rats.
Ågmo, A. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.1.55 · Cited by 68
Mizoguchi, H., Narita, M., Oji, D. E., Suganuma, C., Nagase, H., Sora, I., Uhl, G. R., Cheng, E. Y., & Tseng, L. F. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00298-5 · Cited by 58
Association of Alcohol or Other Drug Dependence with Alleles of the μ Opioid Receptor Gene (OPRM1)
Kranzler, H. R., Gelernter, J., O'Malley, S., Hernandez‐Avila, C. A., & Kaufman, D. (1998) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.1998.tb03919.x · Cited by 58
New δ-opioid antagonists as pharmacological probes
Bryant, S. D., Salvadori, S., Cooper, P. S., & Lazarus, L. H. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01156-5 · Cited by 57
Chefer, V. I., Kieffer, B. L., & Shippenberg, T. S. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02912.x · Cited by 58
Self-citationKumar, D., Chakraborty, J., & Das, S. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.10.018 · Cited by 62
Chefer, V. I., Denoroy, L., Zapata, A., & Shippenberg, T. S. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06827.x · Cited by 57
“The generation of mice lacking MOPr has been described previously (Matthes et al., 1996; Filliol et al., 2000).”
Background
Metadata
- Authors
- Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Surrey (GB)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Inserm (FR)
- Venue
- Nature
- Published
- 1996-10
- Volume
- 383
- Issue
- 6603
- Pages
- 819-823
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051746492
- Cited by
- 1,722
- References
- 25
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 45 · 2023: 52 · 2022: 53 · 2021: 56 · 2020: 59 · 2019: 56 · 2018: 53 · 2017: 43 · 2016: 59 · 2015: 53 · 2014: 60 · 2013: 65 · 2012: 58
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- mu-opioid receptor, morphine, analgesia, opioid reward, place preference, opioid withdrawal, physical dependence, knockout mice, delta opioid receptor, kappa opioid receptor, opioid system, pain management
- MeSH terms
- Analgesics, Animals, Behavior, Animal, Cell Line, Enkephalins, Mice, Inbred C57BL, Morphine, Morphine Dependence, Narcotics, Reward, Substance Withdrawal Syndrome, Gene Deletion, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa, Mice, Knockout, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.